Topic Hub
9 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 9 of 9 clinical reviews.
Retatrutide is not FDA-approved for heart failure, but early trial data on weight loss and cardiometabolic markers suggest potential benefit. Here is what clinicians and patients should know about off-label use, dosing, and the current evidence base.
Read clinical reviewRetatrutide is an investigational triple-agonist peptide not approved for heart failure. Learn what early data suggest, how clinicians monitor off-label use, and what trials to watch.
Read clinical reviewRetatrutide is an investigational triple-agonist not approved for any indication. Here is what clinicians should know about its potential off-label use in heart failure, including evidence gaps, mechanistic promise, and safety concerns.
Read clinical reviewRetatrutide is not FDA-approved for NASH. Learn what the phase 2 trial data actually show, how the triple-agonist mechanism maps to NASH biology, and what clinicians and patients need to weigh before considering off-label use.
Read clinical reviewIs retatrutide a viable off-label option for obstructive sleep apnea? We review the phase 2 trial data, proposed dosing protocols, FDA status, and what clinicians need to know before prescribing.
Read clinical reviewWhat does the clinical evidence say about using retatrutide off-label for obstructive sleep apnea? We review trial data, weight-loss outcomes, AHI reductions, and how this triple-agonist compares to approved therapies.
Read clinical reviewRetatrutide is a triple-hormone receptor agonist showing up to 24.2% body weight reduction in Phase 2 trials. Learn about off-label dosing protocols, safety data, and how it compares to approved GLP-1 therapies.
Read clinical reviewA clinical evidence summary of retatrutide for weight loss, including phase 2 trial data, mechanism of action, dosing, safety profile, and current regulatory status of this investigational triple-receptor agonist.
Read clinical reviewRetatrutide is an investigational triple-agonist showing up to 24% body weight reduction in Phase 2 trials. Learn about off-label use, safety data, and how it compares to approved GLP-1 options.
Read clinical review